Patients with hematologic malignancies are already prone to infection, and treatment-related neutropenia further heightens that risk. Fever during significant neutropenia is different: infection can progress quickly, and inflammatory signs may be weak or absent. Febrile neutropenia (FN) therefore requires prompt clinical assessment and empiric antimicrobial treatment.
The ANC alone does not capture the risk. A short period of neutropenia after chemotherapy is not equivalent to the profound neutropenia that may persist for weeks after acute leukemia treatment or hematopoietic cell transplantation. The malignancy, treatment, duration of neutropenia, mucosal injury, previous infections, and other immune deficits all matter.
What Is Febrile Neutropenia?
Neutropenia generally refers to an ANC below 1,500/µL, with infection risk rising as the count falls. An ANC below 500/µL is commonly considered severe neutropenia, below 100/µL, it is profound. Infection risk is highest when profound neutropenia lasts more than seven days, a pattern common during intensive treatment of hematologic malignancies.
FN occurs when fever develops during severe neutropenia or when the ANC is expected to fall into that range. Fever definitions vary slightly between guidelines and institutions. Severe infection does not always produce a prominent fever: corticosteroids and immunosuppression can blunt the inflammatory response, so rigors, hypotension, confusion, dyspnea, severe weakness, or new abdominal or perianal pain can signal serious infection even when fever is absent.
The lowest blood count reached after treatment is called the nadir. Its timing depends on the regimen, dose, previous therapy, marrow reserve, underlying disease, and use of G-CSF. The often-quoted “7-14 day nadir” is not universal.
Febrile Neutropenia Does Not Look the Same Across Hematologic Cancers
The pattern of FN differs across hematologic malignancies. Acute leukemia combines disease-related marrow failure with treatment-induced aplasia. Lymphoma more often produces cyclical treatment-related neutropenia. In multiple myeloma, infection risk can remain substantial even after neutrophils recover.
Prolonged Neutropenia in Acute Myeloid Leukemia
Marrow function is often already compromised at diagnosis, and intensive induction adds prolonged, profound neutropenia on top of that. Mucositis, central venous access, repeated antimicrobial exposure, and long hospital stays compound it further.
The risk doesn’t end once remission is reached. Intermediate- or high-dose cytarabine consolidation brings recurrent bouts of severe neutropenia, and FN remains one of the leading reasons for readmission after consolidation in contemporary series. CPX-351 carries the same burden in a different form: randomized data show slower neutrophil and platelet recovery than with conventional 7+3.
Even the newer, ostensibly gentler regimens aren’t exempt. In the phase 3 VIALE-A trial, azacitidine plus venetoclax produced FN in 42% of patients versus 19% with azacitidine plus placebo, and grade 3 or higher neutropenia in 42% versus 28%, despite venetoclax-based treatment being less intensive than conventional induction. Marrow assessment and count recovery help guide cycle timing.
Myelodysplastic Syndromes: Disease and Treatment Can Both Suppress Counts
Many patients with higher-risk MDS are already neutropenic before treatment starts, a consequence of ineffective hematopoiesis. Hypomethylating agents then deepen those cytopenias during early cycles.
The combination adds up. A phase 1b study of treatment-naive higher-risk MDS found FN in 42.1% of patients receiving azacitidine plus venetoclax at the recommended phase 2 dose, with neutropenia in 48.6% and treatment interruptions required in most patients.
Diffuse Large B-Cell Lymphoma: Risk Is Often Front-Loaded
Real-world data from more than 1,100 patients receiving R-CHOP showed an overall FN rate of approximately 20%, with many first episodes occurring during the first treatment cycle.
Primary G-CSF prophylaxis was considerably more common with R-CHOP-14, one reason the same regimen name can carry different real-world FN rates. Older age, advanced disease, poor performance status, comorbidities, low albumin, anemia, and bone marrow involvement were all associated with greater risk. Because the first episode clusters so early, risk assessment and G-CSF prophylaxis matter from cycle one, before a patient’s actual tolerance is known.
Indolent Lymphomas
Follicular lymphoma and other indolent lymphomas resist a single number entirely: the treatment spectrum runs from observation to antibody-based therapy, chemoimmunotherapy, targeted agents, and multiple later-line options, so assigning one FN risk to “indolent lymphoma” as a category says very little.
You can also read:
Acute Lymphoblastic Leukemia: Infection Risk Across Treatment Phases
In ALL, risk moves with the phase of treatment. It peaks during induction and intensive consolidation, when neutropenia, mucosal injury, and corticosteroid exposure all overlap. Maintenance is gentler on the marrow, but prolonged exposure to 6-mercaptopurine, methotrexate, and, in some protocols, corticosteroid pulses keeps a different kind of immunosuppression in the background.
After transplantation, infection risk extends well past neutrophil engraftment, particularly with graft-versus-host disease. Even the newer agents don’t equalize this: blinatumomab is generally gentler on the marrow than intensive chemotherapy, while inotuzumab-containing salvage regimens can still carry substantial risk.
Multiple Myeloma: Infection Risk Can Persist After ANC Recovery
Myeloma is the clearest case for looking past the ANC altogether. Profound prolonged neutropenia isn’t even a reliable feature of standard therapy here, yet infection remains a major source of morbidity, because the disease itself impairs normal humoral immunity independent of the marrow.
BCMA-directed bispecific antibodies make this especially visible: they cause neutropenia alongside prolonged hypogammaglobulinemia and defects in B- and T-cell immunity, and across studies reviewed by an expert panel, infections occurred in roughly 33%-76% of treated patients, with wide variation between agents. Opportunistic infections such as Pneumocystis jirovecii pneumonia and viral reactivation have also been reported.
CAR T-cell therapy creates a similar picture: cytopenias may persist or develop after the early treatment period, and hypogammaglobulinemia and lymphocyte dysfunction can continue well after neutrophils have recovered.
You can also read:
Where Does Infection Come From During Neutropenia?
Many infections originate from organisms already carried by the patient. Chemotherapy-related mucosal injury allows oral or gastrointestinal flora to cross damaged barriers, central venous catheters provide another route into the bloodstream.
Previous antibiotics and colonization with resistant organisms can alter the pathogens involved. Common pathogens include Gram-negative and Gram-positive bacteria, fungi such as Candida and Aspergillus, and viral infections or reactivations (particularly herpesviruses and respiratory viruses).
How Is a Patient With Febrile Neutropenia Assessed?
Initial assessment includes vital signs and hemodynamic stability, examination for an infectious source, complete blood count, biochemical tests, and blood cultures. Additional microbiological testing and imaging follow the symptoms and immune status of the patient.
An infectious source is often not apparent at presentation, and cultures may remain negative. Antibiotics are therefore started, testing should not delay treatment.
General Principles of Febrile Neutropenia Treatment
High-risk FN usually requires inpatient intravenous treatment. Expected neutropenia lasting more than seven days generally places a patient in the high-risk group. Shorter neutropenia can still be high risk if clinical instability, significant comorbidities, organ dysfunction, uncontrolled disease, or other adverse features are present.
Intensive leukemia therapy and hematopoietic cell transplantation commonly fall into this category. Initial treatment for high-risk FN includes an antipseudomonal beta-lactam. Options are cefepime, piperacillin/tazobactam, meropenem, or imipenem, selected according to local resistance patterns.
Broader therapy is not automatically required because neutropenia is profound. Routine addition of vancomycin or another glycopeptide is also unnecessary. Additional gram-positive coverage is reserved for specific indications: selected catheter-related infections, skin or soft-tissue infection, pneumonia, hemodynamic instability, or a relevant resistant pathogen.
Selected low-risk patients may be treated as outpatients. Clinically stable patients with neutropenia expected to last seven days or less and no major risk factors may qualify for oral outpatient treatment. MASCC or CISNE scores can support assessment. Outpatient care also requires reliable oral medication use, close follow-up and access to urgent reassessment.
The MASCC Risk Index looks at how clinically stable a patient is when febrile neutropenia develops. It gives greater weight to features suggesting clinical stability, particularly a low symptom burden, absence of hypotension, and absence of COPD. Additional points are given for no dehydration, outpatient onset, and age under 60 years, with disease-related factors also contributing.
These points are combined into a total score of up to 26. Unlike many risk scores, a higher MASCC score is reassuring: ≥21 indicates low risk of serious complications, and a score <21 identifies patients at higher risk. This was developed and validated in a broad population of patients with cancer, many of whom had solid tumors and relatively short durations of neutropenia.
Persistent fever does not automatically mean treatment failure. Fever may continue for several days despite appropriate antibacterial therapy, particularly during profound neutropenia. In a stable patient with negative cultures and no new infection focus, persistent fever alone does not justify repeatedly broadening antibiotics. New hypotension, respiratory compromise, organ dysfunction, new localizing symptoms, microbiological evidence of resistance, or deterioration should trigger reassessment.
When Should Antifungal Treatment Be Considered?
Persistent or recurrent fever during prolonged profound neutropenia raises concern for invasive fungal disease. Pre-emptive strategies based on imaging and fungal diagnostics can reduce unnecessary antifungal exposure. In high-risk patients without systemic antifungal prophylaxis, current AGIHO guidance supports mold-active antifungal treatment when fever persists or recurs after approximately 72-96 hours of appropriate antibacterial therapy. Routine empiric antifungal treatment is not recommended for standard-risk FN.
Antibiotics Do Not Always Continue Until Neutrophils Recover
Empiric antibacterial treatment was traditionally continued until ANC recovery. More recent evidence supports earlier discontinuation in selected clinically stable patients.
Current AGIHO guidance allows empiric antibiotics to be stopped after sustained defervescence and clinical recovery even when neutropenia persists. Randomized data in high-risk hematologic malignancies found that stopping after at least 72 hours of apyrexia and clinical recovery reduced antibiotic exposure without requiring neutrophil recovery first. This approach requires close monitoring.
Can Febrile Neutropenia Be Prevented?
G-CSF. G-CSF shortens chemotherapy-induced neutropenia and reduces FN in appropriate settings. Primary prophylaxis is based on the FN risk of the regimen together with patient-specific factors. Secondary prophylaxis may be used after a previous neutropenic complication when maintaining treatment intensity is clinically relevant.
For regimens with intermediate FN risk, older age, poor performance status, previous chemotherapy, marrow involvement, baseline cytopenias, comorbidities, and previous FN can influence the decision. Observed FN rates should be interpreted alongside G-CSF use, since the same regimen can show different real-world rates depending on how consistently prophylaxis is applied.
Antimicrobial prophylaxis. Antibacterial and antifungal prophylaxis is mainly used. Antiviral and Pneumocystis jirovecii prophylaxis may be indicated in specific treatment settings. AML induction, transplantation, ALL therapy, and some cellular or bispecific antibody treatments therefore need different preventive strategies than a short neutropenic nadir after conventional lymphoma chemotherapy. Hand hygiene, oral and skin care, food safety, and appropriate central-line care remain practical preventive measures.
You can also read:
Neutrophil Recovery Does Not Always Mean Immune Recovery
FN developed as a framework for managing infection during cytotoxic chemotherapy, and it remains highly relevant. But the CAR T-cell and BCMA-directed therapies now used in myeloma and other hematologic cancers expose its limits most clearly: ANC can normalize even as hypogammaglobulinemia and lymphocyte dysfunction persist, leaving a patient at meaningful infection risk that a neutrophil count alone will not capture.
The same principle extends across hematologic cancers more broadly. Fever or clinical deterioration during significant neutropenia should not wait for the next scheduled test.
FAQ
Can you have a serious infection with a normal neutrophil count?
Yes. Neutrophil recovery does not necessarily mean full immune recovery. This is particularly relevant after CAR T-cell therapy and with BCMA-directed therapies, where hypogammaglobulinemia and lymphocyte dysfunction can persist despite normalization of the ANC.
Can you have neutropenic sepsis without a fever?
Yes. Profound immunosuppression or corticosteroid treatment can blunt the inflammatory response. Hypotension, rigors, confusion, shortness of breath, marked weakness, or new abdominal or perianal pain can therefore be important warning signs even without a prominent fever.
Why is the first chemotherapy cycle sometimes the riskiest for febrile neutropenia?
Some chemotherapy regimens show a front-loaded pattern of risk. In real-world R-CHOP data, many first episodes of febrile neutropenia occurred during cycle 1, meaning risk assessment and preventive strategies need to be considered before a patient’s individual treatment tolerance is known.
Does a negative blood culture rule out infection in febrile neutropenia?
No. An infectious source may never be microbiologically documented, and cultures can remain negative despite clinically important infection. This is one reason empiric antibiotics are started promptly rather than waiting for microbiological confirmation.
Can febrile neutropenia be treated at home?
Selected low-risk patients can receive outpatient treatment, but a risk score alone is not enough. Patients should be clinically stable, have no major high-risk features, and have reliable access to medication, follow-up, and urgent reassessment if their condition changes.
Why are fungal infections particularly concerning during prolonged neutropenia?
Prolonged profound neutropenia weakens an important component of antifungal defense. Persistent or recurrent fever in this setting can therefore raise concern for invasive fungal disease and may prompt targeted imaging, fungal diagnostics, and, in appropriate high-risk patients, mold-active therapy.
Do antibiotics have to continue until the neutrophil count recovers?
Not always. In selected clinically stable patients who have become afebrile and recovered clinically, contemporary approaches allow antibiotics to be discontinued before ANC recovery, provided close monitoring is available.